Johnson & Johnson's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Total-Cashflows-From-Financing-Activities" stands at -5.51 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025.
Johnson & Johnson's third quarter result of -8.93 Billion USD for the item "Total Cashflows From Financing Activities" represents a decrease of -57.58 percent compared to it's second quarter result.
Also, Johnson & Johnson's third quarter result of -8.93 Billion USD for the item "Total Cashflows From Financing Activities" represents an increase of 9.66 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Johnson & Johnson's third quarter result of -5.51 Billion USD for the item "Total Cashflows From Financing Activities" represents an increase of 14.77 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 0.937 Billion United States Dollars compared to the value the year prior.
The 1 year change is 0.937 Billion United States Dollars.
The 3 year change is 8.50 Billion United States Dollars.
The 5 year change is -0.962 Billion United States Dollars.
The 10 year change is 2.66 Billion United States Dollars.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Total Cashflows From Financing Activities | 905,699,262,464.00 |
![]() | AbbVie Inc - Total Cashflows From Financing Activities | 399,570,305,024.00 |
![]() | Roche Holding AG - Total Cashflows From Financing Activities | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Total Cashflows From Financing Activities | 280,205,508,085.11 |
![]() | Novartis AG - Total Cashflows From Financing Activities | 255,096,620,580.91 |